

1 **Title:** Noncommunicable diseases associated with hemorrhagic
2 disorders, hospitalization and mortality in patients with dengue in
3 Mexico: a national analysis of confirmed cases in 2024

4 **Short title:** Noncommunicable diseases and dengue in Mexico in 2024

5
6 Diego Rolando Hernández Galdamez¹, Miguel Ángel González-Block^{2,3,4}, Daniela Karola
7 Romo-Dueñas^{1,5}, Erick Antonio Osorio López^{1,6*}, Rosalba Cerón-Meza⁷, Pablo Méndez-
8 Hernández^{7,8}

9
10 ¹Escuela de Salud Pública de México, Cuernavaca, Morelos, México

11 ²Universidad Anáhuac, Ciudad de México, México

12 ³Instituto Nacional de Salud Pública, Cuernavaca, Morelos, México

13 ⁴Evisys Consulting, Ciudad de México, México

14 ⁵Centro de Estudios en Salud, Universidad del Valle de Guatemala, Ciudad de Guatemala,
15 Guatemala

16 ⁶Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad de México,
17 México

18 ⁷Facultad de Agrobiología, Universidad Autónoma de Tlaxcala, Tlaxcala, México.

19 ⁸Hospital General de Tlaxcala, Secretaría de Salud de Tlaxcala, Tlaxcala, México.

20

21 *Corresponding Author

22 E-mail: erickosoriolopez@comunidad.unam.mx

23

24 **Abstract**

25

26 **Background**

27 In Mexico, some of the most prevalent non-communicable diseases (NCDs) among adults
28 are diabetes, hypertension, and chronic kidney disease (CKD). Mexico could be going
29 through a syndemic of dengue and NCDs. This study aims to describe and analyze the
30 association between the prevalence of NCDs and hospitalization, the presence of
31 hemorrhagic disorders, and death in all officially confirmed cases of dengue in Mexico
32 during 2024.

33

34 **Methodology/Principal Findings**

35 This cross-sectional study is carried out through a secondary analysis of the confirmed
36 cases of dengue reported in 2024. The likelihood of hospitalization, hemorrhagic disorders,
37 and death were assessed according to NCDs, estimating odds ratios (ORs). A multivariate
38 logistic regression model was used, adjusting by age, sex, and for each of the NCDs
39 (diabetes, hypertension, chronic kidney disease, immunosuppression, cirrhosis, and peptic
40 ulcer disease). The most co-prevalent non-communicable diseases were diabetes,
41 hypertension, CKD, and immunosuppression. For hospitalization, CKD has the highest risk
42 of hospitalization (OR 5.73), followed by immunosuppression (OR 2.84), peptic ulcer
43 disease (OR 2.35), and diabetes (OR 2.09). We found higher probabilities for having
44 bleeding disorders in people with diabetes (OR 19.51), peptic ulcer disease (OR 7.85),
45 immunosuppression (OR 4.75), cirrhosis (OR 3.37), and hypertension (OR 2.99) compared
46 to people who did not have these diseases. The highest risk for death was observed in the

47 cases with CKD (OR 6.54), followed by peptic ulcer disease (OR 3.09) and diabetes (OR
48 2.87).

49

50 **Conclusions/Significance**

51 Patients with dengue and some comorbidities were more likely to have worse clinical
52 outcomes, such as being hospitalized, having bleeding disorders, or dying. The syndemic of
53 NCDs and dengue in Mexico has been rapidly increasing, and this problem needs to be
54 addressed. This work demonstrates that patients with these comorbidities have worse
55 clinical outcomes.

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71 **Introduction**

72 Dengue is a viral infection caused by Dengue flavivirus (DENV), which belongs to the
73 RNA Flaviviridae virus family. DENV commonly hosts mosquitoes as vectors of these
74 species, like *Aedes aegypti*, transmit the DENV to humans (1). These mosquitoes are
75 spreading their reach due to climate change and global warming, posing disease control
76 challenges in areas previously free from dengue. (2). Dengue is considered a neglected
77 tropical infection with high endemicity, especially in Latin America (3). According to the
78 Pan American Health Organization (PAHO), 2024 is outlined to record the highest number
79 of dengue cases since 1980. For Latin America, this represents a 70% increase in reported
80 confirmed cases from 2023 (2,053,822) to 2024 (6,916,684). Mexico reported a rise of
81 126.3% in confirmed cases from 2023 (54,406) to 2024 (123,142) (4). Brazil has the
82 highest incidence in the Americas (5).

83

84 Severe dengue (SD) is a complication that generally occurs when the fever goes away and
85 is accompanied by intense abdominal pain, vomiting, bleeding in the gums or nose, or
86 vomiting blood or blood in the stool, among other symptoms. These are known as warning
87 signs (WS) that require immediate medical attention, which may or may not require
88 hospitalization (6). Previous studies have identified some characteristics that can serve as
89 predictors for developing severe dengue. A 2021 meta-analysis that included studies from
90 the Americas identified children, secondary infection, diabetes, and renal disease as
91 predictors for severe dengue (7). Another study considers chronic kidney disease (CKD) as
92 a high-risk factor for developing WS and SD, especially in those with end-stage renal
93 disease on maintenance dialysis (8).

94 Mexico could be going through a syndemic of neglected diseases, such as dengue and non-
95 communicable diseases (NCD). In the Mexican context, the prevalence of NCDs among
96 adults is diabetes (18.3%), hypertension (29.9%), and CKD (9.11%) (9–11). There is solid
97 evidence that the presence of pre-existing NCD triggers severe illness and increases the risk
98 of mortality in those who get severe dengue (12,13). A recent study in México identified
99 that diabetes and CKD were associated with increased mortality risk (14).

100 Identifying predictive factors of severe dengue disease is useful in prioritizing interventions
101 for preventing dengue transmission and urgent measures for NCD prevention and control
102 (13). This study aims to describe and analyze the association between the prevalence of
103 NCDs and hospitalization, the presence of hemorrhagic disorders, and death in all official
104 confirmed dengue cases reported in Mexico during 2024.

105

106 **Methods**

107 *Databases and data extraction*

108 This cross-sectional study is carried out through a secondary analysis of the confirmed
109 dengue cases reported by the Federal Ministry of Health (MoH) of Mexico through the
110 anonymized and open-access database published through the Directorate General of
111 Epidemiology.

112

113 The MoH database, from January 1, 2024, to December 4, 2024, reported 117,495
114 laboratory-confirmed dengue cases. The following variables were extracted and assessed.
115 For sociodemographic status: age, sex, ethnicity, and social security affiliation. For
116 noncommunicable diseases: diabetes, hypertension, chronic kidney disease,
117 immunosuppression, cirrhosis, and peptic ulcer disease. For outcome variables:

118 hospitalization, presence of hemorrhagic disorders, and deceased. The descriptors in the
119 database do not define the classification method for comorbidities. The information is
120 obtained through a dichotomous questionnaire that the interviewer fills with the
121 information provided by the patient.

122

123 The study does not require ethical review because it is based on open, anonymized data
124 from the Mexican Ministry of Health.

125

126 *Statistical Analysis*

127 Categorical variables were described as percentages. χ^2 and Fisher's exact tests were
128 performed to compare the proportions of patients with and without noncommunicable
129 diseases against the proportions of patients with and without hospitalization, hemorrhagic
130 disorders, and death. The likelihood of hospitalization, hemorrhagic disorders, and death
131 were assessed according to pre-existing medical conditions, estimating odds ratios (ORs)
132 with 95% confidence intervals and their corresponding p values. A multivariate logistic
133 regression model was used, adjusting by age, sex, and for each of the noncommunicable
134 diseases (diabetes, hypertension, chronic kidney disease, immunosuppression, cirrhosis,
135 and peptic ulcer disease). All statistical analysis was performed using Stata MP software,
136 version 14.0 (Stata Corporation, College Station, TX, USA).

137

138 **Results**

139 Of the total confirmed dengue cases in 2024, 55.66% were women. The age group with the
140 highest concentration of cases was adults aged 20 to 44 (41.83%), followed by adolescents
141 (26.52%). Only 2.42% of reported cases occurred in Indigenous people. 46.04% of the

142 population have social security (IMSS, ISSSTE, Sedena, Pemex, or Semar). The most co-
 143 prevalent non-communicable diseases were diabetes (2.97%), hypertension (2.47%), CKD
 144 (0.26%), and immunosuppression (0.17%) (Table 1).

145

146 **Table 1. General characteristics of patients with dengue and condition of**
 147 **hospitalization, hemorrhagic disorders, and mortality, Mexico 2024**

Variables	Total confirmed cases n=117,495	In-patient cases n= 45,568		Cases with hemorrhagic disorders n=1,028		Deceased cases n= 776	
	n (%)	n (%)	p	n (%)	p	n (%)	p
Sex							
Women	65,401(55.66)	25,913 (56.87)	0.000*	630 (61.28)	0.000*	428 (55.15)	0.775*
Men	52,094 (44.34)	19,655 (43.13)		398 (38.72)		348(44.85)	
Age group							
< 5	3,077 (2.62)	1,439 (3.16)	0.000*	4 (0.39)	0.000*	31 (3.99)	0.000*
5-9	9,324 (7.94)	4,158 (9.12)		11 (1.07)		52 (6.70)	
10-19	31,161 (26.52)	13,987 (30.69)		32 (3.11)		119 (15.34)	
20-44	49,154 (41.83)	16,804 (36.88)		245 (23.83)		242 (31.19)	
45-59	16,186 (13.78)	5,276 (11.58)		395 (38.42)		112 (14.43)	
>60	8,593 (7.31)	3,904 (8.57)		341 (33.17)		220 (28.35)	
Ethnicity							
Indigenous	2,843 (2.42)	860 (1.89)	0.000*	32 (3.11)	0.146*	21(2.71)	0.558**
No Indigenous	114,652 (97.58)	44,708 (98.11)		996 (96.89)		755 (97.29)	
Social security affiliation							
With social security	54,089 (46.04)	20,394 (44.76)	0.000*	548 (53.31)	0.000*	283 (36.47)	0.000*
Without social security	63,406 (53.96)	25,174 (55.24)		480 (46.69)		493 (63.53)	
Comorbidity							
Diabetes	3,488 (2.97)	1,930 (4.24)	0.000*	461 (44.84)	0.000*	123 (15.85)	0.000*
Hypertension	2,906 (2.47)	1,527 (3.35)	0.000*	22 (2.14)	0.490*	81 (10.44)	0.000**
Chronic kidney disease	310 (0.26)	253 (0.56)	0.000*	24 (2.33)	0.000**	33 (4.25)	0.000**
Immunosuppression	196 (0.17)	131 (0.29)	0.000*	13 (1.26)	0.000**	6 (0.77)	0.002**
Cirrhosis	95 (0.08)	55 (0.12)	0.000*	6 (0.58)	0.000**	2 (0.26)	0.131**
Peptic ulcer disease	59 (0.05)	40 (0.09)	0.000*	11 (1.07)	0.000**	5 (0.64)	0.000**

148 * χ^2 test **Fisher's exact test

149

150 According to the data analysis, 38.7% (45,568) of the confirmed dengue cases were

151 hospitalized, among which hospitalized women were 56.87%. In the case of hospitalized

152 patients, the most frequent age group was 20-44 years (36.88%), followed by 10-19 years
153 (30.69%). 55.24% of the in-patients' cases didn't have social security affiliation. We found
154 a higher prevalence of NCDs in hospitalized patients compared to outpatients. We found a
155 higher prevalence of NCDs in hospitalized patients compared to outpatients: diabetes
156 (4.24% vs. 2.17%), hypertension (3.35% vs 1.92%), and CKD (0.56% vs 0.08%). It was
157 reported that 0.87% (1,028) of confirmed cases presented hemorrhagic disorders, of which
158 61.28% were women. In this case, the age groups with the highest incidence of bleeding
159 disorders were adults aged 45 to 59 (38.42%) and adults over 60 (33.17%). Among those
160 who had hemorrhagic disorders, 44.84% had diabetes, and 2.88% had CKD as the most
161 prevalent comorbidity. No significant differences were found concerning sex or ethnicity.
162 Regarding mortality, 63.53% of them didn't have social security affiliation. The age group
163 in which most fatal cases occurred was young adults aged 20 to 44 (31.19%), followed by
164 older adults (28.35%). Among patients with diabetes and hypertension, we observed higher
165 mortality rates compared to the population without these NCDs (3.53% vs 0.57% and
166 2.79% vs 0.61%, respectively). The most prevalent comorbidities in patients who died were
167 diabetes (15.85%), hypertension (10.44%), and CKD (4.25%) (Table 1).
168
169 Regarding sociodemographic variables, we found significant differences in mortality rates
170 between people with social security and people who did not have social security (36.5 vs
171 63.5%, respectively). On the other hand, the indigenous population had a lower
172 hospitalization rate in comparison to no indigenous people (30.2% vs 38.9%), despite the
173 similarity in mortality rates between the groups.
174 Patients with dengue and some comorbidities were more likely to have worse clinical
175 outcomes, such as being hospitalized, having bleeding disorders, or dying. For

176 hospitalization, the analysis reported that women were 1.10 times more likely to be
177 hospitalized than men. A higher risk was reported for patients older than 60 (OR 1.19)
178 compared with children under 5. The rest of the age groups between 5 and 59 years old
179 were less likely to be hospitalized than children under 5 (ORs from 0.97 to 0.65). Among
180 NCDs, CKD has the highest risk of hospitalization (OR 5.73), followed by
181 immunosuppression (OR 2.84), peptic ulcer disease (OR 2.35), and diabetes (OR 2.09)
182 (Table 2).

183

184 Concerning hemorrhagic disorders, women were more likely to have them than men (OR
185 1.19). The age groups at greatest risk of hemorrhagic dengue were adults aged 45 to 59,
186 followed by older adults (OR 3.27), compared to children under 5 years of age.

187 Interestingly, when analyzing people with dengue and comorbidities, very high
188 probabilities were found for having bleeding disorders in people with diabetes (OR 19.51),
189 peptic ulcer disease (OR 7.85), immunosuppression (OR 4.75), cirrhosis (OR 3.37) and
190 hypertension (OR 2.99) (Table 2).

191

192 Regarding mortality, of the total number of confirmed cases of dengue, 776 people died
193 (0.66%). People without social security had a higher risk of dying (OR 1.66). All the older
194 age groups were less likely to die than children under 5 years of age (ORs from 0.44 to
195 0.07). The highest risk for death was observed in the cases with CKD (OR 6.54), followed
196 by peptic ulcer disease (OR 3.09) and diabetes (OR 2.87). Finally, we identified those who
197 presented with hemorrhagic disorders had a higher risk of hospitalization (OR 2.67, 95% CI
198 2.35-3.02) and death (OR 3.70, 95% CI 2.68-5.12). (Table 2)

199

200 **Table 2. Adjusted odd ratios for hospitalization, hemorrhagic disorders, and mortality**
 201 **in dengue-confirmed cases in Mexico 2024.**

Variables	In-patient cases n= 45,568			Cases with hemorrhagic disorders n=1,028			Deceased cases n= 776		
	Adjusted odds ratio	95% CI	p	Adjusted odds ratio	95% CI	p	Adjusted odds ratio	95% CI	p
Sex									
Men	1			1			1		
Women	1.10	1.07-1.13	0.000	1.19	1.05-1.35	0.007	0.92	0.80-1.06	0.291
Age group									
<5	1			1			1		
5-9	0.93	0.86-1.01	0.096	0.75	0.24-2.37	0.629	0.44	0.28-0.68	0.000
10-19	0.97	0.89-1.04	0.406	0.51	0.18-1.45	0.208	0.22	0.14-0.33	0.000
20-44	0.65	0.58-0.71	0.000	1.34	0.48-3.75	0.577	0.13	0.07-0.21	0.000
45-59	0.65	0.57-0.74	0.000	3.27	1.09-9.76	0.033	0.07	0.03-0.14	0.000
>60	1.19	1.01-1.41	0.043	2.84	0.87-9.26	0.084	0.12	0.05-0.27	0.000
Ethnicity									
No Indigenous	1			1			1		
Indigenous	0.67	0.63-0.74	0.000	1.25	0.87-1.79	0.226	1.11	0.72-1.71	0.647
Social security affiliation									
With social security	1			1			1		
Without social security	1.06	1.04- 1.09	0.000	0.85	0.75-0.96	0.010	1.66	1.43-1.92	0.000
Comorbidity*									
Diabetes	2.09	1.94-2.25	0.000	19.51	16.90- 22.53	0.000	2.86	2.26-3.65	0.000
Hypertension	1.59	1.47-1.73	0.000	0.04	0.02-0.06	0.000	1.17	0.87-1.56	0.296
Chronic kidney disease	5.73	4.28-7.69	0.000	2.99	1.74-5.15	0.000	6.54	4.32-9.89	0.000
Immunosuppression	2.84	2.09-3.86	0.000	4.75	2.41-9.33	0.000	1.76	0.14-4.46	0.228
Cirrhosis	1.89	1.25-2.88	0.003	3.37	1.16-9.75	0.025	0.79	0.14-4.46	0.789
Peptic ulcer disease	2.35	1.32-4.17	0.004	7.85	3.3-18.9	0.000	3.09	1.08-8.88	0.036

202 *Compare without each comorbidity
 203 Odds Ratio were adjusted by age, sex, and for each of the comorbidities analyzed.
 204

205 Discussion

206 In this study, we have found consistent findings concerning previous studies. Our results
 207 suggest that the presence of pre-existing NCDs in people with dengue is strongly associated
 208 with hospitalization, the development of hemorrhagic disorders, or death.

209

210 In the case of hospitalization, although they were not the most prevalent, the NCDs that
211 were most associated were CKD, immunosuppression, and peptic ulcer disease; in the case
212 of the presence of bleeding disorders, diabetes, peptic ulcer disease, and
213 immunosuppression; finally, in the case of death, CKD, diabetes and peptic ulcer disease.
214 We also identified women and the extremes of life, i.e., children under five and adults over
215 60, as a risk group associated with a higher probability of hospitalization. However, adults
216 aged 45 to 59 and over 60 had the highest probability of presenting hemorrhagic disorders,
217 which can be explained by the prevalence of NCDs in this age group compared to children.
218 Our analysis has limitations concerning the variable of “hemorrhagic disorders” given that
219 there is no further information on what was considered to classify the confirmed cases with
220 the presence of these. The lack of information prevents us from classifying the cases as
221 dengue with warning signs or severe dengue, according to Mexican Standards. (15). In the
222 latter document, severe dengue is only considered when there is already shock due to
223 extravasation, severe bleeding (for example, hematemesis, melena), or organ failure. This
224 type of information is not included in the database, so we consider the presence of this
225 condition as a warning sign (WS). Nor can we know if the appearance of these warning
226 signs was before or after hospitalization. However, we consider this variable to be a key
227 predictor and strong proxy for severe dengue because of its association with hospitalization
228 and death, and its association with some NCDs is the main contribution of our study.
229
230 Our results are consistent with the findings of other studies identifying CKD and diabetes
231 as the main NCDs for the risk of severe dengue and death (7,8,14). In the case of the study
232 by Rios-Bracamontes et al., our ORs are slightly higher for CKD (6.54 vs. 3.35) and
233 diabetes (2.86 vs. 2.07) (14). It is important how other NCDs, such as peptic ulcer disease,

234 play an important role as they are associated with a higher probability of hospitalization,
235 bleeding, and death. This can be explained by the risk per se that these pathologies have,
236 like cirrhosis, of causing upper gastrointestinal bleeding, and this generates a synergistic
237 factor with dengue (16). Therefore, the antecedent of peptic ulcer disease should be
238 urgently considered by clinicians as a predictor for these outcomes.

239 Although Mexico has a low case fatality rate (0.66%) compared to other countries in the
240 region, if we compare it with Brazil, which has the highest incidence of cases in the
241 Americas, the latter's case fatality rate has ranged between 0.04 and 0.09% in the last 10
242 years (2,17). This reinforces the need for epidemiological surveillance systems for
243 suspicious cases and to classify them according to risk factors to avoid complications. One
244 of the most important early predictors must be the appearance of WS, among the most
245 important being signs of bleeding, according to our study, the NCDs most associated with
246 these hemorrhagic disorders are diabetes, peptic ulcer disease, and immunosuppression, in
247 addition to CKD. To this, we would add being a woman and being in the over-45 age group
248 to identify a risk group that is slightly different from the one usually considered (under 5
249 years of age). Therefore, the clinical approach following confirmation of a case of dengue
250 should be risk classification according to these predictors and consider early
251 observation/hospitalization.

252

253 The National Health Program 2020–2024 proposed intersectoral actions to mitigate the
254 impact of climate change on health, although no specific mention is made of the syndemic
255 between neglected diseases and diseases associated with global warming and NCDs (18).
256 Other countries have proposed specific actions to monitor the impact of global warming

257 among people living with NCDs and to develop health system adaptations to address the
258 syndemic. (19,20).

259

260 **Conclusions**

261

262 The syndemic of NCDs and dengue in Mexico has been rapidly increasing, and this
263 problem needs to be addressed. This work demonstrates that patients with these
264 comorbidities have worse clinical outcomes. Further research is needed to better understand
265 the effect of sociodemographic conditions on clinical outcomes in patients with dengue in
266 Mexico.

267

268 Finally, the monitoring of health risks posed by global warming should consider the
269 population living with NCDs, given the higher risk posed by dengue to these populations,
270 as well as the high prevalence of NCDs in Mexico.

271

272 **References**

- 273 1. Pourzangiabadi M, Najafi H, Fallah A, Goudarzi A, Pouladi I. Dengue virus:
274 Etiology, epidemiology, pathobiology, and developments in diagnosis and control – A
275 comprehensive review. Vol. 127, Infection, Genetics and Evolution. Elsevier B.V.; 2025.
- 276 2. Almeida MT de, Merighi DGS, Visnardi AB, Gonçalves CAB, Amorim VM de F,
277 Ferrari AS de A, et al. Latin America's Dengue Outbreak Poses a Global Health Threat.
278 Viruses 2025, Vol 17, Page 57 [Internet]. 2025 Jan 1 [cited 2025 Feb 5];17(1):57.
279 Available from: <https://www.mdpi.com/1999-4915/17/1/57/htm>

- 280 3. Alied M, Endo PT, Aquino VH, Vadduri VV, Huy NT. Latin America in the
281 clutches of an old foe: Dengue. *The Brazilian Journal of Infectious Diseases*. 2023 Jul
282 1;27(4):102788.
- 283 4. Pan American Health Organization. PAHO/WHO Data - Dengue [Internet]. 2025
284 [cited 2025 Feb 8]. p. 1. Available from: [https://www3.paho.org/data/index.php/en/mnu-](https://www3.paho.org/data/index.php/en/mnu-topics/indicadores-dengue-en.html)
285 [topics/indicadores-dengue-en.html](https://www3.paho.org/data/index.php/en/mnu-topics/indicadores-dengue-en.html)
- 286 5. Gallego-Munuera M, Colomé-Hidalgo M. Letalidad por dengue y desigualdades en
287 la Región de las Américas entre el 2014 y el 2023. *Revista Panamericana de Salud Pública*
288 [Internet]. 2024 Dec 18 [cited 2025 Feb 5];48:1. Available from:
289 <https://iris.paho.org/handle/10665.2/62938>
- 290 6. Organización Mundial de la Salud. Dengue y dengue grave [Internet]. 2025 [cited
291 2025 Feb 13]. p. 1. Available from: [https://www.who.int/es/news-room/fact-](https://www.who.int/es/news-room/fact-sheets/detail/dengue-and-severe-dengue)
292 [sheets/detail/dengue-and-severe-dengue](https://www.who.int/es/news-room/fact-sheets/detail/dengue-and-severe-dengue)
- 293 7. Tsheten T, Clements ACA, Gray DJ, Adhikary RK, Furuya-Kanamori L, Wangdi K.
294 Clinical predictors of severe dengue: a systematic review and meta-analysis. *Infect Dis*
295 *Poverty* [Internet]. 2021;10(1):123. Available from: [https://doi.org/10.1186/s40249-021-](https://doi.org/10.1186/s40249-021-00908-2)
296 [00908-2](https://doi.org/10.1186/s40249-021-00908-2)
- 297 8. Chen HJ, Tang HJ, Lu CL, Chien CC. Warning signs and severe dengue in end-
298 stage renal disease dialysis patients. *Journal of Microbiology, Immunology and Infection*
299 [Internet]. 2020;53(6):979–85. Available from:
300 <https://www.sciencedirect.com/science/article/pii/S1684118219301379>
- 301 9. Basto-Abreu A, López-Olmedo N, Rojas-Martínez R, Aguilar-Salinas CA, Moreno-
302 Banda GL, Carnalla M, et al. Prevalencia de prediabetes y diabetes en México: Ensanut

- 303 2022. *Salud Publica Mex* [Internet]. 2023 Jun 13;65:s163–8. Available from:
304 <https://www.saludpublica.mx/index.php/spm/article/view/14832>
- 305 10. Campos-Nonato I, Oviedo-Solis C, Hernández-Barrera L, Márquez-Murillo M,
306 Gómez-Álvarez E, Alcocer-Díaz L, et al. Detección, atención y control de hipertensión
307 arterial. *Salud Publica Mex* [Internet]. 2024 Aug 22;66(4, jul-ago):539–48. Available from:
308 <https://saludpublica.mx/index.php/spm/article/view/15867>
- 309 11. Institute for Health Metrics and Evaluation (IHME). GBD Compare [Internet]. 2021
310 [cited 2025 Feb 13]. p. 1. Available from: <https://vizhub.healthdata.org/gbd-compare/>
- 311 12. Yang CH, Leeid IK, Chen YC, Huang WC, Hsu JC, Tai CH, et al. Prognostic
312 factors in severe dengue patients: A multi-center retrospective cohort study. Samy AM,
313 editor. *PLoS Negl Trop Dis* [Internet]. 2025 Jan 28 [cited 2025 Feb 5];19(1):e0012846.
314 Available from: <https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0012846>
- 315 13. Mehta P, Hotez PJ. NTD and NCD Co-morbidities: The Example of Dengue Fever.
316 Vol. 10, *PLoS Neglected Tropical Diseases*. Public Library of Science; 2016.
- 317 14. Ríos-Bracamontes EF, Mendoza-Cano O, Lugo-Radillo A, Ortega-Ramírez AD,
318 Murillo-Zamora E. Factors Contributing to In-Hospital Mortality in Dengue: Insights from
319 National Surveillance Data in Mexico (2020–2024). *Trop Med Infect Dis*. 2024 Sep
320 3;9(9):202.
- 321 15. Instituto de Diagnóstico y Referencia Epidemiológicos. Lineamientos para la
322 Vigilancia por Laboratorio. Dengue y otras arbovirosis [Internet]. Ciudad de México; 2021
323 [cited 2025 Feb 13]. Available from:
324 [https://www.gob.mx/cms/uploads/attachment/file/629265/Lineamientos_Dengue_Arb_V1-](https://www.gob.mx/cms/uploads/attachment/file/629265/Lineamientos_Dengue_Arb_V1-2021.pdf)
325 2021.pdf

- 326 16. Wang JY, Tseng CC, Lee CS, Cheng KP. Clinical and upper gastroendoscopic
327 features of patients with dengue virus infection. *J Gastroenterol Hepatol* [Internet]. 1990
328 Dec 1;5(6):664–8. Available from: <https://doi.org/10.1111/j.1440-1746.1990.tb01122.x>
- 329 17. Agência Brasil. Dengue cases in Brazil surpass 6.4M in 2024 [Internet]. 2025 [cited
330 2025 Feb 13]. p. 1–2. Available from:
331 [https://agenciabrasil.ebc.com.br/en/saude/noticia/2025-01/dengue-cases-brazil-surpass-](https://agenciabrasil.ebc.com.br/en/saude/noticia/2025-01/dengue-cases-brazil-surpass-64m-2024)
332 [64m-2024](https://agenciabrasil.ebc.com.br/en/saude/noticia/2025-01/dengue-cases-brazil-surpass-64m-2024)
- 333 18. Gobierno de México. Programa sectorial de salud 2020-2024 [Internet]. 2020 [cited
334 2025 Feb 17]. p. 1–42. Available from:
335 https://dof.gob.mx/nota_detalle.php?codigo=5598474&fecha=17/08/2020#gsc.tab=0
- 336 19. Bambrick HJ, Capon AG, Barnett GB, Beaty RM, Burton AJ. Climate Change and
337 Health in the Urban Environment: Adaptation Opportunities in Australian Cities. *Asia*
338 *Pacific Journal of Public Health* [Internet]. 2011 Jan 17;23(2_suppl):67S-79S. Available
339 from: <https://doi.org/10.1177/1010539510391774>
- 340 20. Lachlan M, Rokho K, Alistair W, Simon H, Jeffery S, Dianne K, et al. Health
341 Impacts of Climate Change in Pacific Island Countries: A Regional Assessment of
342 Vulnerabilities and Adaptation Priorities. *Environ Health Perspect* [Internet]. 2016 Nov
343 1;124(11):1707–14. Available from: <https://doi.org/10.1289/ehp.1509756>